NasdaqGM - Delayed Quote USD

Helix Acquisition Corp. II (HLXB)

10.86

-0.07

(-0.64%)

At close: May 2 at 4:00:00 PM EDT

BridgeBio Oncology and Helix enter definitive merger agreement

The transaction will complete in the third quarter of 2025.

Pharmaceutical Technology last month

BBIO

HLXB
-0.64%
Helix Acquisition to Merge With BridgeBio Oncology Therapeutics

Helix Acquisition Corp. II (HLXB) and TheRas, which does business as BridgeBio Oncology Therapeutics

PREMIUM
MT Newswires 2 months ago

BBIO

HLXB
-0.64%
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

SOUTH SAN FRANCISCO & BOSTON, February 28, 2025--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, and Helix Acquisition Corp. II (Nasdaq: HLXB) ("Helix"), a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management, today announced that they have entered into a definitive business combination

Business Wire 2 months ago

HLXB
-0.64%

Performance Overview

Return	HLXB	S&P 500 (^GSPC)
YTD	+3.43%	-3.31%
1-Year	+5.03%	+12.29%
3-Year	+8.28%	+36.85%